Welcome to our dedicated page for TransAlta SEC filings (Ticker: TAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hydro turbines in Alberta, wind farms in Washington, and gas peakers in Western Australia鈥擳ransAlta鈥檚 diversified fleet adds layers of complexity to every disclosure. Tracking environmental liabilities, capacity contracts, and fuel-hedge positions across six business segments can turn a 40-F into a week-long project. If you have ever searched for 鈥淭ransAlta insider trading Form 4 transactions鈥� only to wade through pages of footnotes, you know the challenge.
Stock Titan solves this problem. Our AI reads each new filing the moment it hits EDGAR, then delivers plain-English answers to questions investors actually ask, such as 鈥淭ransAlta quarterly earnings report 10-Q filing details鈥� or 鈥淭ransAlta 8-K material events explained.鈥� One dashboard surfaces every document type鈥�10-K equivalents, 6-K updates, DEF 14A proxy statements, Form 4 insider reports, even credit agreements鈥攕o you see the full picture in real time. AI-powered summaries highlight segment revenue shifts, greenhouse-gas disclosures, and asset-retirement obligations, while side-by-side comparisons reveal trends most readers miss.
Use the feed to:
- Receive alerts on 鈥淭ransAlta Form 4 insider transactions real-time鈥� and spot buying or selling by executives.
- Dive into a 鈥淭ransAlta annual report 10-K simplified鈥� view to track capital spending on renewables vs. gas.
- Review a 鈥淭ransAlta proxy statement executive compensation鈥� breakdown without scrolling hundreds of pages.
- Export tables from any 鈥淭ransAlta earnings report filing analysis鈥� to model cash flows faster.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) 鈥� Fiscal Q2 2025 10-Q highlights
- Revenue inflection: Total Q2 revenue jumped to $44.1 million (up 264% YoY) driven by a $30 million license fee from Sanofi and higher collaboration revenue from existing partnerships with Sanofi, Gilead and Pfizer.
- Operating costs accelerate: R&D expense expanded 60% YoY to $78.1 million as the company advanced clinical programs (NX-5948, NX-2127, NX-1607) and DAC discovery work; G&A rose 22% to $14.3 million.
- Loss narrows modestly for the quarter: Net loss was $43.5 million (-$0.52 per share) versus $44.5 million (-$0.71) a year ago, helped by the one-time license payment and a larger share count. For the six-month period, however, the loss widened to $99.8 million.
- Cash runway: Cash, cash equivalents and marketable securities totaled $485.8 million at 31 May 2025, down from $609.6 million at FY-end. Operating cash burn reached $124.2 million in the first half. Management believes existing liquidity funds operations for at least 12 months.
- Collaboration momentum: 鈥� Gilead extended the research term by two years, triggering a $15 million payment.
鈥� Sanofi exercised two target license options, providing $30 million.
鈥� Pfizer collaboration produced $10 million in research milestones to date. - Equity activity: 76.4 million shares outstanding after ATM issuances; stockholders鈥� equity fell to $447.6 million from $527.0 million on higher deficit.
Overall, Nurix continues to monetize its DEL-AI platform through partner payments while accelerating internal R&D, resulting in higher cash burn and sustained losses.
FAQ
What is the current stock price of TransAlta (TAC)?
What is the market cap of TransAlta (TAC)?
What is TransAlta Corporation?
What types of energy sources does TransAlta utilize?
How does TransAlta generate revenue?
In which geographical regions does TransAlta operate?
What makes TransAlta's business model unique?
How does TransAlta support community growth?
What are the key segments of TransAlta's operations?
How does TransAlta differentiate itself from competitors?
